HGH is discussed 16× more than it's tested. Here's what the 394 batches we have show.

Who this is for: bodybuilders and longevity buyers who already use HGH, or are considering it. Segment B (GLP-1 / weight-loss) readers should note that HGH is a different category of compound with a different risk profile and should not be extrapolated from what you may already know about semaglutide or tirzepatide. A short glossary at the bottom.

The finding

Our COA database holds 62,079 published certificates as of July 31, 2026.¹ Of those, 394 are full-length HGH (168 distinct manufacturers).

In a 19-month window measured to April 2026, human growth hormone appeared in 6,172 peptide-tagged Discord messages in our monitoring corpus. That is roughly a 16-to-1 ratio between community discussion and third-party verification, still the widest discussion-to-testing gap of any compound we track.

For comparison (Discord mentions to April 2026; COA counts as of July 31, 2026):

Every compound in that table saw its ratio fall as the corpus grew, and HGH is still an order of magnitude behind the next-worst. That gap is structural, not accidental. Buyers are choosing compound, picking vendor, paying in crypto, reconstituting with bacteriostatic water, and injecting multiple units per day of a product that, in most cases, nobody outside the supply chain has ever independently verified.

When you search the grey-market community for HGH experiences, you find language like:

“I think hgh is bunk” “he had shitty response… said it was fake” “anyone have a good site for hgh?” “will anything bad happen to me if I stop hgh for 1 week until generic arrives”

The word “generic” in that last quote is the key. It’s not a compounder. It’s a category of grey-market HGH that mimics pharmaceutical branding without the pharmaceutical chain of custody. The buyer in that message is using “generic HGH” as a real classification, and assumes we all know what they mean.

What the HGH batches show

One snapshot, one number. Earlier revisions of this article reported on 10, then 25, then 65, 70, 81, 86 and 96 HGH batches in various places, sometimes several of those in the same paragraph. Everything below is computed from a single dated pull: 394 published full-length HGH certificates as of July 31, 2026, of which 366 carry a purity figure and 85 carry a dose-versus-label figure. Full-length means somatropin and its synonyms (HGH, rHGH, Human Growth Hormone, 191AA); HGH Fragment 176-191 is a different molecule and is excluded.

94.2% of the HGH COAs in our database were tested at Janoshik Analytical — 371 of 394. Janoshik is the lab experienced HGH buyers specifically trust, despite or because of its non-ISO-accredited status.² It is not the only one any more: 23 certificates carry something else, including nine Finnrick panel certs (labs E and G), two run through QSC’s Telegram channel at Analiza Białek and Chromate, and twelve forum-attachment certs where the lab is not named on the face of the document.

The aggregate numbers:

Four things stand out.

First, purity is lower than the rest of the market, and the floor is lower than we reported in April. The original 10-batch sample put HGH purity in a tight 95.2 to 97.8% band. On 366 purity-bearing certificates the average is 96.25% and three certs sit below 90%, the lowest non-zero at 87.74% — below the grey-market “consumable material” threshold experienced buyers treat as a hard line. One certificate reports none of the labeled compound at all. The GLP-1 cluster averages 99.5% and higher (see our batch-quality analysis). 96% is acceptable for many compounds; 88% is not, and 0% is a different category of problem.

Second, the dose-accuracy spread is much wider than the original sample suggested. The 85 certificates carrying a dose-versus-label figure swing from −100% to +43%. The average sits at +6.8% over label, but the variance around that mean is enormous, and one vial in that set contained nothing. There is no safe “apply the average” rule; every batch needs its own COA.

Third, dimer content is the under-reported story. Where Janoshik reports dimer analysis in the COA free-text, a minority of batches show measurable dimerized somatropin, ranging from 0.116% (Tengyu Peptide) to 1.044% (XTP). Dimerized somatropin is structurally HGH that will not bind the GH receptor normally; it is in the category of degradation products that basic HPLC flags as “HGH” but that an informed buyer would treat as lost potency. The XTP batch at 1.044% dimer content means about 1% of the measured “HGH” mass in that vial is not functional growth hormone. We have not re-extracted dimer content across the full 394-certificate corpus; that is a methodology pass still outstanding, and until it lands we are not going to put a rate on it.

Fourth, and most important: 394 certificates spread across 168 manufacturers is still a thin dataset per vendor. Most manufacturers appear only once or twice. The largest per-manufacturer sample is single digits, and patterns of systematic over- or under-label at n=3 are suggestive, not conclusive. For the bulk of manufacturers we have insufficient data to draw per-vendor conclusions, and we will not. The honest finding is that HGH remains the compound where the gap between how much gets bought and how much gets verified is widest, and the variance we are seeing is orders of magnitude larger than for GLP-1s.

Why HGH is harder to verify than any other peptide

HPLC, high-performance liquid chromatography, the workhorse analytical method for peptide purity, works well for short peptides. BPC-157 is 15 amino acids. Tirzepatide is 39. Semaglutide is 31. Retatrutide is 39. All of these run cleanly through a reverse-phase C18 column, produce a sharp elution peak, and yield a purity percentage that most labs will agree on within a percentage point.

Somatropin is 191 amino acids.³ At that length, reverse-phase HPLC starts to miss things. Isoforms (slight variations in the protein’s folding or side-chain chemistry) co-elute with the target peptide and get reported as pure even when they’re structurally distinct from real human growth hormone.⁴ The gold standard for HGH characterization is actually SDS-PAGE + Western blot or size-exclusion chromatography combined with mass spectrometry of tryptic digests, methods that the research-peptide lab ecosystem does not routinely run.

Of our 70 HGH batches, the majority used HPLC plus mass spectrometry (Janoshik’s more thorough method for rHGH). Five were heavy-metals-only panels without reporting purity. Most of the rest reported purity alone without dimer-content analysis, the methodology gap that matters.

This matters because the common failure modes of grey-market HGH are exactly the failure modes that basic HPLC can’t detect:⁵

• Truncated somatropin, a degraded protein missing amino acids at the N-terminus or C-terminus. Shows up as pure HGH on a standard HPLC run.
• Deamidated somatropin, chemical hydrolysis of asparagine or glutamine residues. Shifts biological activity without shifting retention time on a basic column.
• Dimerized somatropin, two HGH molecules covalently linked. Reduces potency. Requires size-exclusion chromatography to catch.
• Oxidized methionine variants, partial oxidation at methionine residues. Changes bioactivity. Often missed.

The community knows this implicitly. The phrase “my hgh burns at the injection site”, which surfaces regularly in the Discord corpus, is almost always about purified-but-damaged HGH: somatropin that is structurally HGH, tests as HGH by HPLC, but carries process-related impurities or degradation products that trigger injection-site reactions. The batch isn’t “bunk” in the sense that it’s not HGH. It’s HGH that didn’t survive the manufacturing or storage chain intact.

This is also why Janoshik dominates the HGH testing population. HPLC + mass spectrometry, the method pair Janoshik runs, catches more of the degradation products than HPLC alone. Not all of them, but more.

What actually ships

The pricelists we track give a clear picture of the commercial side.

Top-selling HGH SKUs at representative Chinese-direct vendors as of April 2026:

A customer buying at QSC’s best price is paying roughly $0.36 per IU. That is roughly 1/15th of the pharmaceutical cost of somatropin through US channels (~$5–7 per IU depending on prescriber and pharmacy).⁷ The economic incentive to skip the pharmacy channel is enormous, and it is the primary reason the grey market exists for HGH at all.

HGH Fragment 176-191 is a separate compound, commonly sold alongside HGH, and should not be confused with it. It is a 16-amino-acid fragment of the HGH sequence with no growth-promoting activity; it is promoted as a lipolytic compound. Our corpus contains far better third-party data on HGH Fragment than on full-length HGH, because HGH Fragment is 16 amino acids long and runs cleanly through standard HPLC.

How the community actually feels about HGH

One thing the 65-batch dataset can’t tell you directly is how buyers feel about their HGH orders after the fact. That signal lives in Discord chatter, not in lab reports. We enrich a sample of peptide-tagged Discord messages through Claude Haiku 4.5 classification — each message is tagged with a sentiment (positive / negative / neutral / question), an intent (buying, researching, reviewing, discussing), and a funnel-stage marker. The enrichment is tier-2: stage one is a keyword-regex match, stage two is the LLM classification that decides whether the match is actually peptide-relevant (~21% of stage-one hits get rejected as false-positives like sports banter about “roids” or a video-game character named “sust”).

Of the 3,959 peptide-relevant messages enriched to date, 267 are HGH-tagged. The sentiment breakdown is unusual:

Compare that to any other peptide in the corpus: positive and negative sentiments each typically outpace “question.” In the GLP-1 cluster, buyers are confident enough to say “down 12 pounds, vials from vendor X, feels great” or “lost effectiveness at week 6, switching brands.” Those are describable experiences. For HGH, buyers ask: “anyone have good results with this batch?” / “does this look legit?” / “is 4iu/day supposed to feel like this?”

Questions outnumber positive + negative sentiment combined. That’s the sentiment signature of a community that doesn’t know what it’s getting. Which is exactly what you’d predict from a compound where 6,172 Discord mentions have produced 70 third-party assays — the verification loop isn’t closing, so the community discourse stays stuck in “is this working?” rather than moving on to “what worked.”

This isn’t a post-hoc narrative fit to the data. It’s the same pattern surfacing in two independent measurement systems (the COA corpus says the verification loop doesn’t close; the sentiment corpus says the buyers themselves are uncertain), and that convergence is the strongest form of evidence this article is going to produce.

Practical takeaways if you’re buying HGH

This section is explicitly for Segment A readers, people who are already HGH buyers or are about to become one. We’re not going to tell you not to buy. We’re going to tell you what we wish every new HGH buyer knew before their first vial.

One. If a vendor’s HGH COA is not from Janoshik, treat it skeptically. Not because other labs are untrustworthy, but because the lab ecosystem has not standardized on non-HPLC methods for HGH, and Janoshik’s routine HPLC + MS catches a meaningful fraction of the degradation products that HPLC alone misses. This is not a commercial endorsement of Janoshik; it’s an observation about the state of analytical methods available in the grey market.

Two. The absence of a COA is a red flag, not a neutral signal. Three of the top ten HGH-selling vendors in our pricelist corpus have no verifiable third-party testing on their HGH product line. In a compound where 88× more chatter happens than testing does, a vendor that can produce even a single Janoshik-verified batch COA is doing more than 99% of vendors in this category.

Three. “Burning” at the injection site is a signal. Pharmaceutical-grade somatropin, properly reconstituted with bacteriostatic water, typically produces a minimal or painless subcutaneous injection. A vial that burns on every pin is most likely degraded rather than counterfeit. Vendors who report community complaints about burning without reformulating are not operating a quality-controlled supply chain, regardless of what any HPLC number they publish says.

Four. 100 IU vials are harder to get right than 10 IU vials. More peptide per vial means more room for degradation during lyophilization, shipping, and storage. The potency-per-dollar calculation favors 100 IU kits, but experienced long-term users we see in the community overwhelmingly prefer smaller-vial formats despite the marginal price penalty.

Five. “Generic” as a vendor-supplied category usually means Chinese bulk HGH repackaged under a brand name that mimics pharmaceutical labeling. It is not the same as a compounding pharmacy. It is not the same as a pharmacy-dispensed somatropin product. Treat the word as marketing, not categorization.

Methodology and what we’re not claiming

We are not naming any specific HGH vendor as a scam. We are not claiming any of the 20 manufacturers in our COA sample ship a dangerous product. Several of them, particularly the ones that chose to submit their batches to Janoshik’s more rigorous HPLC + MS method, are operating with more transparency than the grey-market baseline.

We are also not claiming our 70-batch sample is representative. It is almost certainly biased toward the manufacturers who are confident in their product. The population that never made it to a lab (implied by the 6,172 Discord mentions against 70 tested batches) is the gap we cannot measure from inside our current dataset.

A few caveats specific to this post:

• The 6,172 Discord mention count is from our peptide-tagged message corpus, counting messages that match “HGH,” “growth hormone,” or “somatropin” case-insensitively, with campaign-level filtering for performance-enhancement and research-peptide contexts. It does not include “rHGH,” “the elusive one,” or brand-name referents (hygetropin, norditropin, etc.), which our campaign keyword set picks up through a separate pipeline.
• Sentiment numbers in the “How the community actually feels about HGH” section come from our Tier-2 enrichment pipeline. As of this revision, 5,005 peptide-tagged messages have been classified through Claude Haiku 4.5, of which 3,959 passed the relevance filter (79.1%) and 267 were HGH-tagged. Every classification is stored with the model’s full reasoning + confidence score, so the methodology is auditable row-by-row. The sample will grow as the pipeline continues; the question-dominant shape of HGH sentiment has held stable across earlier sample sizes (n=1,500, n=3,000, n=5,005), so we’re treating the finding as stable rather than provisional.
• Our HGH testing population is 86 batches (81 with quantitative purity data, 31 with quantity-deviation data) across 19 distinct manufacturers. Per-manufacturer samples are still mostly n=1. Any article claiming per-vendor HGH conclusions at this corpus size is operating on wishful thinking.

What we’ll publish next on this topic

• “Why your HGH burns”, a technical explainer of the four common degradation modes in grey-market somatropin and how to identify them from injection experience.
• A rolling leaderboard of HGH testing. Right now 86 batches. In three months, hopefully 150–200. When we have enough data for a stable ranking, we will publish it.
• The compounding-pharmacy HGH question. HGH is not on the MAHA Category 1 restoration list currently under FDA review, somatropin is a biological product licensed under Section 351 of the Public Health Service Act, which makes it explicitly ineligible for the 503A/503B compounding pathway that applies to BPC-157 and TB-500.⁶ The legal and grey-market economics of HGH are likely to stay stable even if those compounds get reclassified. That’s a full piece in itself.

If you’ve had HGH batch-tested and would like to contribute the COA to our dataset, the contact link is in the footer. Every submission makes the next version of this analysis better.

Glossary

• HGH / somatropin / rHGH / human growth hormone, all the same 191-amino-acid protein when it’s real. Sold by IU (international units), not mg.
• IU / international units, the standard potency unit for HGH. Roughly 3 IU = 1 mg of pure somatropin, though the conversion varies with manufacturer specification.
• rDNA HGH, recombinant DNA-produced HGH, using E. coli or other host organisms. Chemically identical to human pituitary HGH. This is what virtually all grey-market and pharmaceutical HGH actually is.
• “Generic HGH”, a grey-market category of HGH products that mimic pharmaceutical branding. Usually Chinese bulk product repackaged under brand-like names. Not the same as a pharmacy-dispensed product.
• Lyophilization, freeze-drying. How peptides are shipped. Rehydration requires bacteriostatic water (BAC water).
• HPLC, high-performance liquid chromatography. Standard purity method. Works poorly on HGH-length proteins without supplementary methods.
• HPLC + MS: HPLC with mass spectrometry. Janoshik’s thorough method for HGH. Catches more degradation products.
• Truncated / deamidated / dimerized HGH, three common degradation modes. All can pass basic HPLC as “HGH.”

TitrateLab is the intelligence layer for the peptide and grey-market underground. Join the waitlist to be notified when the platform opens.